(NASDAQ: MNKD) Mannkind's forecast annual revenue growth rate of 15.08% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 64.61%, and while it is forecast to beat the US market's average forecast revenue growth rate of 10.18%.
Mannkind's revenue in 2025 is $285,504,000.On average, 3 Wall Street analysts forecast MNKD's revenue for 2025 to be $97,211,769,897, with the lowest MNKD revenue forecast at $94,811,576,731, and the highest MNKD revenue forecast at $99,823,869,821. On average, 3 Wall Street analysts forecast MNKD's revenue for 2026 to be $111,730,722,332, with the lowest MNKD revenue forecast at $101,035,199,283, and the highest MNKD revenue forecast at $120,820,247,172.
In 2027, MNKD is forecast to generate $133,848,869,699 in revenue, with the lowest revenue forecast at $124,736,575,509 and the highest revenue forecast at $142,961,163,890.